Literature DB >> 24171821

Breast cancer: current developments in molecular approaches to diagnosis and treatment.

Jo-Anne de la Mare, Lara Contu, Morgan C Hunter, Buhle Moyo, Jason N Sterrenberg, Karim C H Dhanani, Lorraine Z Mutsvunguma, Adrienne L Edkins1.   

Abstract

Due to the high heterogeneity of breast cancers, numerous recent patents describe improved methods of detection and classification which promise better patient prognosis and treatment. In particular, there has been a shift towards more effective genetic screening to identify specific mutations associated with breast tumours, which may lead to "personalised medicine" with improved outcomes. Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative breast cancer subtype as well as the chemotherapy-resistant cancer stem cell subpopulation. In addition, despite numerous recent advances in breast cancer treatment in woman, male breast cancer remains poorly understood and there are limited therapies available which are developed specifically for men. This review serves to report on important developments in the treatment of breast malignancies patented in the past two years as well as to highlight the current gaps in the field of breast cancer therapeutics and areas which require further study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24171821     DOI: 10.2174/15748928113086660046

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  22 in total

1.  Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.

Authors:  Huan Gao; Yue Zhang; Lei Dong; Xiao-Yu Qu; Li-Na Tao; Yue-Ming Zhang; Jing-Hui Zhai; Yan-Qing Song
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

2.  dNLR and TILS can be used as indicators for prognosis and efficacy evaluation of neo-adjuvant chemotherapy in breast cancer.

Authors:  Xiaorui Wang; Weipeng Zhao; Lihong He; Shuling Wang; Weidong Li; Jing Wang; Zhongsheng Tong
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

3.  The serum protein profile of early parity which induces protection against breast cancer.

Authors:  Christina Gutierrez Bracamontes; Rebecca Lopez-Valdez; Ramadevi Subramani; Arunkumar Arumugam; Sushmita Nandy; Venkatesh Rajamanickam; Vignesh Ravichandran; Rajkumar Lakshmanaswamy
Journal:  Oncotarget       Date:  2016-12-13

4.  A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?

Authors:  Quentin Haas; Cedric Simillion; Stephan von Gunten
Journal:  Front Oncol       Date:  2018-03-13       Impact factor: 6.244

5.  Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients.

Authors:  Yuanli Huang; Hongtao Wang; Yuanrong Yang
Journal:  Med Sci Monit       Date:  2018-05-27

6.  Assessing Advantages and Drawbacks of Rapidly Generated Ultra-Large 3D Breast Cancer Spheroids: Studies with Chemotherapeutics and Nanoparticles.

Authors:  Austin R Holub; Anderson Huo; Kavil Patel; Vishal Thakore; Pranav Chhibber; Folarin Erogbogbo
Journal:  Int J Mol Sci       Date:  2020-06-21       Impact factor: 5.923

7.  MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.

Authors:  Zhongzeng Liang; Qunwen Pan; Zhi Zhang; Chaosheng Huang; Zeming Yan; Yuanqi Zhang; Jianwen Li
Journal:  Mol Med Rep       Date:  2019-09-24       Impact factor: 2.952

8.  Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients.

Authors:  Paul Dowling; Valentina Palmerini; Michael Henry; Paula Meleady; Vincent Lynch; Jo Ballot; Giuseppe Gullo; John Crown; Michael Moriarty; Martin Clynes
Journal:  BBA Clin       Date:  2014-09-16

9.  MicroRNA-493 is a prognostic factor in triple-negative breast cancer.

Authors:  Ling Yao; Yirong Liu; Zhigang Cao; Junjing Li; Yanni Huang; Xin Hu; Zhiming Shao
Journal:  Cancer Sci       Date:  2018-06-27       Impact factor: 6.716

10.  Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.

Authors:  Xiaoyi Zhang; Xinyu Su; Zhe Guo; Xueqing Jiang; Xun Li
Journal:  J Clin Lab Anal       Date:  2020-03-18       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.